Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1CNS 1

Conditions

Pancreatic Neoplasms 5Melanoma 4Glioblastoma 4Carcinoma 4Breast Neoplasms 4Triple Negative Breast Neoplasms 3Neoplasms 2Fibrolamellar hepatocellular carcinoma 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Merkel Cell 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Smoldering Multiple Myeloma 1Small Cell Lung Carcinoma 1Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasms, Squamous Cell 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lung Neoplasms 1Liver Neoplasms 1

Interventions

pembrolizumab 90Blood Specimen Collection 44Cyclophosphamide 37Nivolumab 35Bevacizumab 35Standard of Care 32Carboplatin 30Surveys and Questionnaires 29Paclitaxel 28atezolizumab 24Pemetrexed 24Gemcitabine 24Exercise 24Fluorouracil 23Cisplatin 23Leucovorin 21Dexamethasone 20Radiotherapy 19Oxaliplatin 19Docetaxel 19Rituximab 16Irinotecan 16Cetuximab 16dostarlimab 15Ipilimumab 15Doxorubicin 15Biopsy 15130-nm albumin-bound paclitaxel 15Drug Therapy 14fludarabine 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × poly ICLC × 1 year × Clear all
NCT06614140 2026-04-22

Personalized Neoantigen Cancer Vaccine for Patients With Solid Tumors

Seqker Biosciences, Inc.

Phase 1/2 Completed
8 enrolled
Tumor-Agnostic

Neoplasms

NCT03223103 2025-09-10

Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma

Albert Einstein College of Medicine

Phase 1 Active not recruiting
13 enrolled
CNS

Brain Neoplasms, Glioblastoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡